WO2006040779A3 - Controlled release gastric floating matrix formulation containing imatinib - Google Patents
Controlled release gastric floating matrix formulation containing imatinib Download PDFInfo
- Publication number
- WO2006040779A3 WO2006040779A3 PCT/IN2005/000333 IN2005000333W WO2006040779A3 WO 2006040779 A3 WO2006040779 A3 WO 2006040779A3 IN 2005000333 W IN2005000333 W IN 2005000333W WO 2006040779 A3 WO2006040779 A3 WO 2006040779A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- controlled release
- formulation containing
- gastric floating
- matrix formulation
- floating matrix
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1049CH2004 | 2004-10-11 | ||
IN1049/CHE/2004 | 2004-10-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006040779A2 WO2006040779A2 (en) | 2006-04-20 |
WO2006040779A3 true WO2006040779A3 (en) | 2006-08-17 |
Family
ID=36148723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2005/000333 WO2006040779A2 (en) | 2004-10-11 | 2005-10-06 | Controlled release gastric floating matrix formulation containing imatinib |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006040779A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY148074A (en) * | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
WO2007106957A1 (en) * | 2006-03-21 | 2007-09-27 | Laboratoires Smb S.A. | Multiple units controlled-release floating dosage forms |
EP1920767A1 (en) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
CA2680249A1 (en) * | 2007-03-12 | 2008-09-18 | Dr. Reddy's Laboratories, Inc. | Imatinib mesylate |
FR2918566B1 (en) | 2007-07-11 | 2009-10-09 | Pierre Fabre Medicament Sa | STABLE PHARMACEUTICAL COMPOSITION OF A WATER SOLUBLE SALT OF VINFLUNINE. |
US20090087489A1 (en) | 2007-09-25 | 2009-04-02 | Bella Gerber | Imatinib compositions |
EP2255792A1 (en) * | 2009-05-20 | 2010-12-01 | Ratiopharm GmbH | Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide |
CZ2009570A3 (en) | 2009-08-26 | 2011-03-09 | Zentiva, K. S. | Preparation, stabilization and use of imatinib mesylate polymorphs for development of medicinal forms |
MX2013001653A (en) | 2010-08-11 | 2013-05-22 | Synthon Bv | Pharmaceutical granulate comprising imatinib mesylate |
WO2012080703A1 (en) * | 2010-12-15 | 2012-06-21 | Cipla Limited | Pharmaceutical composition comprising imatinib |
US9750700B2 (en) * | 2011-06-22 | 2017-09-05 | Natco Pharma Limited | Imatinib mesylate oral pharmaceutical composition and process for preparation thereof |
WO2014041551A1 (en) | 2012-09-14 | 2014-03-20 | Natco Pharma Limited | Formulation comprising imatinib as oral solution |
US20150110871A1 (en) * | 2014-06-02 | 2015-04-23 | David Wong | Gastric retentive tablet compositions |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003090720A1 (en) * | 2002-04-23 | 2003-11-06 | Novartis Ag | High drug load tablet |
WO2003090750A1 (en) * | 2002-04-24 | 2003-11-06 | Board Of Regents, The University Of Texas System | Pdgf receptor tyrosine kinase inhibitors for the treatment of polycythemia vera |
-
2005
- 2005-10-06 WO PCT/IN2005/000333 patent/WO2006040779A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003090720A1 (en) * | 2002-04-23 | 2003-11-06 | Novartis Ag | High drug load tablet |
WO2003090750A1 (en) * | 2002-04-24 | 2003-11-06 | Board Of Regents, The University Of Texas System | Pdgf receptor tyrosine kinase inhibitors for the treatment of polycythemia vera |
Also Published As
Publication number | Publication date |
---|---|
WO2006040779A2 (en) | 2006-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006040779A3 (en) | Controlled release gastric floating matrix formulation containing imatinib | |
US10512621B2 (en) | Methods of treating posttraumatic stress disorder with acamprosate salts | |
FI97686C (en) | Process for producing barley for the manufacture of controlled release products | |
WO2001056544A3 (en) | Shell-and-core dosage form approaching zero-order drug release | |
CN102065847A (en) | Pharmaceutical formulation containing angiotensin-II receptor blocker | |
BR0012981A (en) | Hydrodynamically Balanced Oral Drug Release System | |
WO2002028376A3 (en) | Chrono delivery formulations and method of use thereof | |
US20150250746A1 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
NO20084065L (en) | Quick-release paracetamol tablets | |
CA2065652A1 (en) | Controlled release gastroresistant pharmaceutical formulations for oral administration containing bile acids and their salts | |
WO2007122635A3 (en) | Controlled release formulation comprising anti-epileptic drugs | |
WO2007031887A3 (en) | Extended release pharmaceutical composition of metformin and a process for producing it | |
HUP0004966A3 (en) | Pharmaceutical composition for oral administration in the form of matrix tablet enabling the prolonged release of trimetazidine | |
WO2002024203A3 (en) | Controlled release formulations for oral administration | |
HK1067299A1 (en) | Pharmaceutical compositions containing terbinafineand use thereof | |
WO2007086079A3 (en) | Sustained release dosage form of phenothiazine derivatives containing channelizer | |
CN104379138B (en) | Acamprosate formulations, methods of use thereof, and combinations comprising acamprosate formulations | |
WO2004062552A3 (en) | Pharmaceutical composition containing a nsaid and a benzimidazole derivative | |
CA2516327A1 (en) | Therapeutic system comprising amoxicillin and clavulanic acid | |
WO2009014372A3 (en) | Dispersible tablet comprising coated drug-containing particles and method for the preparation thereof | |
WO2005013935A3 (en) | Composition for releasing a weak base for an extended period of time | |
WO2018206923A1 (en) | Novel formulations | |
US20070009599A1 (en) | Asymmetrically coated table | |
WO2004089333A3 (en) | A stable benzimidazole formulation | |
CN101869708A (en) | Medicament composition containing calcium channel blockers and biguanide antidiabetic medicine and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |